Back

26 January 2026

The ITA reports that triathlete Pedro Afonso Pinto Gaspar has accepted a 3-year sanction for his ADRV

The International Testing Agency (ITA), leading an independent anti-doping program on behalf of World Triathlon, reports that Portuguese triathlete Pedro Afonso Pinto Gaspar has accepted a three-year period of ineligibility after testing positive for the prohibited substance Mesterolone.

¹ Athletes have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the athlete’s case file and establish the applicable consequences pursuant to the anti-doping rules and the athlete will have the right to accept the proposed consequences. If the athlete refuses the proposed consequences, the case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.3.1 and 8.3.3 of the World Triathlon anti-doping rules and 8.3 of the World Anti-Doping Code and is commonly referred to as an agreement on consequences and is deemed a World Triathlon/ITA decision. The athlete’s National Anti-Doping Organisation and the World Anti-Doping Agency have the right to appeal the agreement on consequences before the competent appeal body.

³ Article 10.8.1 of the World Triathlon ADR (and World Anti-Doping Code) provides for a one-year reduction for certain ADRVs based on early admission and acceptance of sanction. This applies where an athlete after being notified by World Triathlon/ITA of a potential ADRV that carries an asserted period of Ineligibility of four (4) or more years, admits the violation and accepts the asserted period of Ineligibility no later than twenty (20) days after receiving notice of an ADRV charge. Where the athlete receives the one-year reduction under Article 10.8.1, no further reduction in the period of Ineligibility is allowed.

Share

Cookie Policy & Privacy Notice

We use cookies on our website to personalize content, to analyze traffic on our website to provide social media features. We share your data with our analytics partners and social media content providers. Find out more

The privacy policy can be accessed here

Your current state: Consent rejected.


Accept Reject Read More